Profile data is unavailable for this security.
About the company
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
- Revenue in EUR (TTM)0.00
- Net income in EUR-2.87m
- Incorporated--
- Employees44.00
- LocationOryzon Genomics SASant Ferran 74CORNELLA DE LLOBREGAT 08940SpainESP
- Phone+34 935151313
- Fax+34 933774028
- Websitehttp://www.oryzon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BenevolentAI SA | 8.69m | -75.07m | 92.75m | 248.00 | -- | 0.7095 | -- | 10.67 | -0.6371 | -0.6371 | 0.0737 | 0.9166 | 0.0473 | -- | 0.3631 | 35,046.57 | -40.88 | -- | -48.87 | -- | -- | -- | -863.69 | -- | -- | -- | 0.048 | -- | -30.58 | -- | 61.38 | -- | -- | -- |
Adocia SA | 2.15m | -21.16m | 96.58m | 78.00 | -- | -- | -- | 44.92 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
Eurofins-Cerep SA | 44.07m | 7.64m | 99.37m | 228.00 | 13.01 | 1.54 | 10.34 | 2.25 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
Maat Pharma SA | 2.23m | -19.72m | 104.39m | 50.00 | -- | 4.26 | -- | 46.85 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
Arcticzymes Technologies ASA | 9.84m | 1.47m | 105.39m | 68.00 | 71.73 | 4.01 | 52.91 | 10.71 | 0.3443 | 0.3443 | 2.30 | 6.17 | 0.3562 | 0.4228 | 6.29 | 1,731,471.00 | 5.31 | 15.58 | 5.66 | 17.22 | 95.50 | 96.69 | 14.91 | 33.23 | 12.14 | -- | 0.0327 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
Transgene SA | 7.63m | -22.33m | 107.48m | 158.00 | -- | 6.83 | -- | 14.08 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
Scope Fluidics SA | 21.75k | -5.29m | 110.05m | 40.00 | -- | 6.35 | -- | 5,059.09 | -8.29 | -8.29 | 0.0341 | 27.18 | 0.0009 | 2.94 | 0.0337 | 2,325.00 | -21.76 | 52.74 | -22.74 | 57.32 | -2,022.58 | -420.87 | -24,304.30 | 30,134.78 | 13.86 | -- | 0.0299 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
Medica SpA | 79.98m | 2.97m | 114.87m | 731.00 | 38.72 | 2.21 | 12.06 | 1.44 | 0.7025 | 0.7025 | 18.94 | 12.33 | 0.6417 | 1.39 | 5.00 | 109,410.10 | 2.00 | 4.26 | 3.17 | 6.34 | 59.45 | 63.25 | 3.12 | 7.16 | 0.8734 | 3.88 | 0.307 | -- | 57.24 | 19.52 | -31.80 | 2.05 | 24.28 | -- |
Inventiva SA | 17.48m | -110.43m | 117.81m | 112.00 | -- | -- | -- | 6.74 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
Oryzon Genomics SA | 0.00 | -2.87m | 120.09m | 44.00 | -- | 1.40 | -- | -- | -0.0431 | -0.0431 | 0.00 | 1.34 | 0.00 | 101.09 | -- | 0.00 | -2.72 | -4.20 | -3.19 | -4.82 | -- | -- | -- | -- | 0.8741 | -3.16 | 0.1487 | -- | -- | -- | 20.76 | -- | 15.52 | -- |
Futura Medical PLC | 3.68m | -7.72m | 121.05m | 12.00 | -- | 18.61 | -- | 32.93 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 5.09 | 258,414.20 | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
Heidelberg Pharma AG | 9.52m | -13.06m | 123.04m | 97.00 | -- | 2.99 | -- | 12.92 | -0.2837 | -0.2837 | 0.2062 | 0.8832 | 0.1270 | 0.194 | 13.23 | 100,234.60 | -17.42 | -43.91 | -22.34 | -64.34 | 82.74 | 52.13 | -137.16 | -206.24 | 4.90 | -- | 0.3417 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
Diamyd Medical AB | 15.84k | -11.89m | 143.84m | 25.00 | -- | 8.90 | -- | 9,078.85 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
Cellectis SA | 11.17m | -72.23m | 145.81m | 235.00 | -- | 1.74 | -- | 13.05 | -1.22 | -1.03 | 0.1639 | 1.16 | 0.04 | -- | 1.41 | 47,550.21 | -27.82 | -24.08 | -42.40 | -30.69 | -- | -64.64 | -694.72 | -308.24 | -- | -- | 0.552 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
Cereno Scientific AB | 0.00 | -5.04m | 148.03m | 5.00 | -- | 7.19 | -- | -- | -0.281 | -0.281 | 0.00 | 0.8598 | 0.00 | -- | -- | 0.00 | -24.71 | -16.81 | -26.65 | -18.26 | -- | -- | -- | -- | -- | -10.70 | 0.1843 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
Holder | Shares | % Held |
---|---|---|
SSgA Funds Management, Inc.as of 03 Jul 2024 | 139.04k | 0.22% |
Dimensional Fund Advisors LPas of 04 Jul 2024 | 75.36k | 0.12% |
Santander Private Banking Gestion SA SGIICas of 31 Dec 2023 | 50.00k | 0.08% |
Gescooperativo SA SGIICas of 31 Dec 2023 | 47.91k | 0.08% |
Tressis Gesti�n SGIIC SAas of 31 Dec 2023 | 45.00k | 0.07% |
Solventis SGIIC SAas of 31 Dec 2023 | 20.00k | 0.03% |
Dimensional Fund Advisors Ltd.as of 04 Jul 2024 | 12.49k | 0.02% |
Gesiuris Asset Management SGIIC SAas of 31 Dec 2023 | 8.00k | 0.01% |
Gesti�n de Patrimonios Mobiliarios AV SAas of 31 Mar 2024 | 4.00k | 0.01% |
Andbank Wealth Management SGIIC SAUas of 31 Dec 2023 | 200.00 | 0.00% |